Placebo News and Research

RSS

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Aradigm Corporation (the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

Investigators urge drug regulators to provide clear evidence on statins’ side effects

At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomised trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them.

13 Mar 2014

Cefaly medical device receives FDA approval for migraine prevention

CEFALY Technology announced today that its received U.S. Food and Drug Administration approval of the Cefaly medical device for the preventative treatment for migraine headaches. Cefaly is the first transcutaneous electrical nerve stimulation (TENS) device specifically authorized for use prior to the onset of pain. It is expected to be available in the U.S. in early April.

13 Mar 2014

N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis

N30 Pharmaceuticals, Inc. announced today that it has begun oral dosing of N91115 in a Phase 1 clinical trial. N91115, a novel inhibitor of S-nitrosoglutathione reductase (GSNOR), is being developed for the treatment of cystic fibrosis (CF).

12 Mar 2014

Parkinson disease patients with higher CSF experience faster cognitive decline

Counterintuitive Findings Offer New Insights into Parkinson Disease Pathology, According to New Research Published in The American Journal of Pathology

12 Mar 2014

NeuroDerm enrolls patients in second ND0612 Phase II clinical trial for treatment of Parkinson's disease

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.

11 Mar 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

High antibody affinity identifies type 1 diabetes

LADA (latent autoimmune diabetes in adults) is a form of type 1 diabetes in adulthood. Like the childhood form, the insulin-producing beta cells of the pancreas are destroyed by the body's own immune system.

11 Mar 2014

Controlled TB vaccine trial designed to study prevention of Mtb infection by vaccination

Aeras today announced the initiation of the first randomized, controlled tuberculosis (TB) vaccine trial designed to study prevention of Mycobacterium tuberculosis (Mtb) infection by vaccination.

11 Mar 2014

Glucosamine not reduces knee cartilage deterioration among individuals with chronic knee pain

A short-term study found that oral glucosamine supplementation is not associated with a lessening of knee cartilage deterioration among individuals with chronic knee pain.

11 Mar 2014

Trophos' olesoxime shows beneficial effect on maintaining motor function in SMA patients

Trophos today announces that top-line results from a pivotal clinical trial of its lead product candidate olesoxime in spinal muscular atrophy (SMA) show a beneficial effect on the maintenance of motor function in SMA patients. If approved, olesoxime could be the first treatment specifically developed for SMA patients.

10 Mar 2014

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg.

10 Mar 2014

Study: Stem cell transplant effective in halting degenerative disc disease of spine

Stem cell transplant was viable and effective in halting or reversing degenerative disc disease of the spine, a meta-analysis of animal studies showed, in a development expected to open up research in humans.

10 Mar 2014

Viewpoints: New delay on policies: Cover for dems or just smoothing the bumps of health law?

The Obama administration announced a new policy on Wednesday that will allow many people to renew their existing insurance policies for two more years even though the policies don't provide the comprehensive coverage and consumer protections required by the Affordable Care Act.

10 Mar 2014

Placebo News and Research

Aradigm reports record revenue of $4.6M in fourth quarter 2013

Investigators urge drug regulators to provide clear evidence on statins’ side effects

Cefaly medical device receives FDA approval for migraine prevention

N30 Pharma begins oral dosing in N91115 Phase 1 trial for treatment of cystic fibrosis

Parkinson disease patients with higher CSF experience faster cognitive decline

NeuroDerm enrolls patients in second ND0612 Phase II clinical trial for treatment of Parkinson's disease

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

High antibody affinity identifies type 1 diabetes

Controlled TB vaccine trial designed to study prevention of Mtb infection by vaccination

Glucosamine not reduces knee cartilage deterioration among individuals with chronic knee pain

Trophos' olesoxime shows beneficial effect on maintaining motor function in SMA patients

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Study: Stem cell transplant effective in halting degenerative disc disease of spine

Viewpoints: New delay on policies: Cover for dems or just smoothing the bumps of health law?

Scientists develop new nasal filter that helps people with nasal symptoms from seasonal hay fever

Just one drink can affect driving abilities of older drivers

Edison Pharmaceuticals initiates Phase 2B/3 study of EPI-743 in children with Leigh syndrome

Study investigates possible links between sleep and omega-3 DHA fatty acid status in healthy children

Alkermes initiates pivotal clinical development program for treatment of MDD

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News